The letter from your ophthalmologist said your retina was stable. You’ve been on semaglutide for four months. Then, last Tuesday, something changed – a grey curtain appeared at the edge of your vision. You waited two days to see if it would resolve.
That was the wrong call.
Some visual changes on GLP-1 therapy are expected and benign. Some are emergencies. The problem is they can look similar from the inside. This guide draws the line clearly.
Why GLP-1 and Vision Are Connected
GLP-1 medications work by changing how your body manages glucose and appetite. What most patients don’t expect is that some of these effects touch the eye.
Two mechanisms are most relevant. First, rapid glucose lowering in people with existing diabetic eye disease can temporarily worsen retinopathy – the blood vessels in the retina, accustomed to years of high glucose, can react adversely when glucose drops quickly.[1] This is called “early worsening” of diabetic retinopathy and is documented in clinical trial data for semaglutide.
Second, there is a separate and debated association between GLP-1 use and non-arteritic anterior ischaemic optic neuropathy (NAION) – a condition where blood supply to the optic nerve is temporarily interrupted. The evidence for this link is still under investigation; a large 2024 pharmacovigilance study raised the concern, while subsequent analyses have produced mixed results.[2] What matters clinically is that NAION presents with sudden, painless vision loss – and it is an emergency.
Understanding which changes fall under which category is the purpose of this guide.
The Triage Framework: Four Categories
Category 1: Go to the Emergency Department Now
These changes require immediate care – not a call to your family doctor, not an appointment tomorrow:
- A grey or dark curtain moving across your visual field – especially if it appears to descend or spread over minutes or hours
- Sudden loss of central vision in one eye – especially if it is painless
- Vision that goes completely dark in one eye for any period (even if it returns)
- Double vision with new headache or facial drooping – this may indicate a neurological event unrelated to your eye
These presentations can indicate NAION, retinal artery occlusion, or vitreous haemorrhage. Time to treatment matters. Do not drive yourself.
Category 2: Call Your Doctor or Ophthalmologist Today
These changes are not immediately catastrophic but should not wait:
- New floaters that appeared suddenly – especially if accompanied by flashes of light
- A new area in your vision where you cannot see (scotoma), even if small
- Blurred vision that began within 2-3 weeks of your GLP-1 dose being increased
- Any vision change in someone with known proliferative diabetic retinopathy – this group has higher baseline risk
Sudden new floaters with flashes can indicate a posterior vitreous detachment, which in some cases progresses to retinal tear. Same-day evaluation is warranted.
Category 3: Schedule Within a Week
These warrant evaluation but are not emergencies:
- Gradual blurring that started several weeks into GLP-1 treatment and has not changed – often tied to transient refractive changes from glucose normalisation, which resolve within two to four weeks[3]
- Mild light sensitivity with no other symptoms
- Eyes feel drier than usual – dry eye has been reported anecdotally with GLP-1 therapy, though direct clinical evidence for reduced tear production with this drug class is limited; mention it to your prescriber rather than assuming it is unrelated
Inform your prescribing doctor and get a baseline ophthalmology check if you haven’t had one in the past year.
Category 4: Track and Wait
Not everything that changes is worrying:
- Vision is slightly different after starting medication – if this has been stable for more than 6 weeks, gradual, and non-alarming, it likely reflects glucose adaptation
- Reading vision feels mildly different – especially if you have never had a recent refraction; this may simply reflect refractive change
- Mild dryness with no visual loss
Track these in writing. Mention them at your next scheduled appointment. Do not ignore them – but do not escalate to the emergency department.
What to Tell the Doctor at Each Level
Whether you go to the ER or call a clinic, the information you communicate in the first 60 seconds matters.
Say this clearly:
“I am on semaglutide [or tirzepatide / Ozempic / Wegovy / Mounjaro / Zepbound]. I have been on it for [X months]. My dose was last changed [X weeks ago]. My vision changed [describe exactly: which eye, what you see, when it started, how fast it changed].”
This helps the clinician immediately consider GLP-1 related mechanisms. Many emergency physicians will not ask about GLP-1 use spontaneously.
Also note: whether you have diabetes and any known diabetic retinopathy status. If you have retinal imaging reports, bring them or note where they are.
Who Has Higher Background Risk
Not everyone on GLP-1 therapy has the same eye risk profile. Your risk of vision-related complications is meaningfully higher if you have:
- Type 2 diabetes with HbA1c that was significantly elevated before starting treatment
- Known diabetic retinopathy (any stage)
- Hypertension that is not well controlled
- Small optic disc anatomy (your ophthalmologist can assess this on routine exam)
- A previous episode of NAION (this increases recurrence risk)
If any of these apply, discuss ophthalmology monitoring with your prescribing doctor before reaching the point where vision changes prompt a call. Proactive retinal imaging at treatment initiation is appropriate in this group.[4]
Evidence Gaps and What Is Still Uncertain
The NAION-GLP-1 association generated significant attention following a 2024 case series at a neuro-ophthalmology referral centre. That study was not population-level, which means it captured severe cases selectively. Population-level pharmacovigilance studies have produced conflicting risk estimates.[2]
What this means in practice: the association is plausible given GLP-1 vascular effects, and the absolute risk remains low. In June 2025, the European Medicines Agency concluded a formal safety review and classified NAION as a “very rare” side effect of semaglutide medicines, estimated at up to 1 in 10,000 patients treated, and the World Health Organization issued a corresponding alert to clinicians.[5] The US FDA has not yet updated semaglutide product labelling to include NAION, though the signal remains under active review there as well.
For patients: this does not mean the risk is zero. It means you should know what sudden vision loss looks like and not wait.
For prescribers: this means baseline ophthalmologic status in at-risk patients is clinically reasonable even absent a formal guideline.
This article is for educational purposes only and does not constitute medical advice. If you experience sudden vision loss or any of the Category 1 symptoms described above, seek emergency care immediately. Educational content about GLP-1 medications and eye health should not replace evaluation by a qualified ophthalmologist or emergency physician.
Track Your Symptoms and Questions Before Your Appointment
Vision changes can be hard to describe under pressure. Tracking exactly what you noticed, when, and how fast it changed, before you walk into a clinic, helps every clinician you speak to.
Join the Field Notes for tools designed for people managing their health with GLP-1 medications, including symptom tracking guidance and appointment preparation checklists.
REFERENCES
[1] Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897. doi:10.1111/dom.13172.
[2] Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296.
[3] Li H-Y, Luo G-C, Guo J, Liang Z. Effects of glycemic control on refraction in diabetic patients. Int J Ophthalmol. 2010;3(2):158-160. doi:10.3980/j.issn.2222-3959.2010.02.15.
[4] Bain SC. GLP-1 receptor agonists and diabetic retinopathy. Diabetes Prim Care. 2021;23:103-104.
[5] European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. 6 June 2025.
